Crisil Ratings has withdrawn its ratings on Symed Labs Ltd following its amalgamation with Viyash Lifesciences Pvt Ltd and subsequent merger with Sequent Scientific Ltd (Viyash). The rating withdrawal, effective January 16, 2026, aligns with Crisil’s policy on withdrawals after the completion of the amalgamation process, confirming that Symed Labs Ltd has ceased to exist as a separate entity.
Rating Withdrawal Details
Crisil Ratings has officially withdrawn its ratings for the bank facilities of Symed Labs Ltd (Symed). The decision follows the completed amalgamation of Symed with Viyash Lifesciences Pvt Ltd (Viyash), and Viyash’s subsequent amalgamation with Sequent Scientific Ltd.
The amalgamation of Symed with Viyash was deemed effective on November 27, 2025, and Viyash’s amalgamation with Sequent became effective on December 16, 2025. The withdrawals are in accordance with Crisil Ratings’ policy on withdrawal of ratings following such corporate actions.
About Symed Labs
Symed, incorporated in 1998, is known for manufacturing active pharmaceutical ingredients (APIs), offering a portfolio of around 50 APIs across various therapeutic segments.
The company has four API plants and one research and development (R&D) center, with all facilities approved by the United States Food and Drug Administration (USFDA), catering primarily to overseas markets.
Financial Performance Snapshot (2025)
Key financial indicators for 2025 include:
- Revenue: Rs.785 Crore
- Profit After Tax (PAT): Rs.120 Crore
- PAT Margin: 15.4%
Source: BSE
